title: Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients.
abstract: The aim of this study is to compare the risk of treatment-related toxicities and long-term survival between obese and nonobese patients with non-Hodgkin lymphoma when treated with full uncapped doses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. A total of 133 patients and 733 cycles of chemotherapy were analyzed. Obese patients did not experience an increased risk of acute treatment-related toxicities (adjusted odds ratio 0.825, p = 0.197), or delayed toxicities (adjusted odds ratio 0.819, p = 0.779). In the subgroup of diffuse large B-cell lymphoma patients (n = 109), treatment response rate was similar between the two body mass index (BMI) groups, and obese patients tended to have superior overall and progression-free survivals, albeit not statistically significant. Full uncapped doses of R-CHOP chemotherapy administered to obese patients with non-Hodgkin lymphoma (NHL) are safe, well tolerated, and do not lead to inferior treatment response or long-term outcomes.
authors.affiliation: a Department of Haematology , Middlemore Hospital , Auckland , New Zealand ;
authors.forename: Henry
authors.initials: H
authors.lastname: Chan
authors.affiliation: a Department of Haematology , Middlemore Hospital , Auckland , New Zealand ;
authors.forename: Sharon
authors.initials: S
authors.lastname: Jackson
authors.affiliation: b Department of Statistics , University of Auckland , Auckland , New Zealand.
authors.forename: Jessica
authors.initials: J
authors.lastname: McLay
authors.affiliation: a Department of Haematology , Middlemore Hospital , Auckland , New Zealand ;
authors.forename: Angela
authors.initials: A
authors.lastname: Knox
authors.affiliation: a Department of Haematology , Middlemore Hospital , Auckland , New Zealand ;
authors.forename: Jae
authors.initials: J
authors.lastname: Lee
authors.affiliation: a Department of Haematology , Middlemore Hospital , Auckland , New Zealand ;
authors.forename: Sarah
authors.initials: S
authors.lastname: Wang
authors.affiliation: a Department of Haematology , Middlemore Hospital , Auckland , New Zealand ;
authors.forename: Samar
authors.initials: S
authors.lastname: Issa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004361:Drug Tolerance; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis* / Q000209:etiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009765:Obesity / Q000150:complications* / Q000175:diagnosis; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Chemotherapy; non-Hodgkin lymphoma; obesity